Margin operasi Syros Pharmaceuticals, Inc. (SYRS)

Simbol resmi perusahaan Syros Pharmaceuticals (SYRS)

Syros Pharmaceuticals (SYRS) innovative approach to reprogramming cancer cells correlates with the fact that operational efficiency dynamics on GURU.Markets contain the value 0.00. The company is currently restructuring its debt and seeking buyers for its patents following unsuccessful tests. However, future share price growth depends on the results of the Phase 3 clinical trials for tamibarotene and FDA approval.

SYRS - Margin operasi Syros Pharmaceuticals Inc. ing rentang 04.07.2022 - 29.03.2025

SYRS (Syros Pharmaceuticals): rincian analitis lan laporan miturut indikator

- rega saham lan konsensus proyeksi valuasi:
Analisis komprehensif perusahaan:Syros Pharmaceuticals Inc., SYRS
Produk dadi Syros Pharmaceuticals, Inc

Outsourcing production to CMO facilities minimizes capital expenditures for Syros Pharmaceuticals (SYRS), directly impacting the efficiency of cost management. This operating profit margin is calculated as the ratio of operating income to revenue, allowing investors to assess the commercial profitability of the business excluding debt obligations and taxes, thereby identifying consolidation phases prior to potential market downturns.

Pesaing utama

Margin dodolan operasi TEM|QGEN - Tingkat bathi adhedhasar bathi operasi|Margin operasi IONS|RGEN - Rentabilitas dodolan operasi|Rentabilitas operasi Avidity RNA|Margin operasi CRISPR Therapeutics Corp CRSP|GeneDx Corp - Margin operasi|Ultragenyx Pharma (RARE) - Margin dodolan operasi|beamtx.com (BEAM) - Rentabilitas operasi|SRPT: Rasio bathi operasi|Margin dodolan operasi TWST|TXG - Tingkat bathi adhedhasar bathi operasi|Margin operasi NTLA|Rentabilitas kegiatan operasi Stoke Therapeutics|Rentabilitas operasi BioLife Solutions BLFS|Wave Life Sciences (WVE) - Rentabilitas dodolan operasi|Maze Therapeutics, Inc. - Margin operasi|Rentabilitas kegiatan operasi Sionna Therapeutics, Inc. SION|Prime Medicine Bio (PRME) - Rentabilitas operasi|TSHA: Rasio bathi operasi|Rentabilitas operasi uniQure Pharma|MGTX - Tingkat bathi adhedhasar bathi operasi|Margin operasi RGNX|Rentabilitas operasi SLDB (Solid Biosciences)|Ocugen Corp - Margin dodolan operasi|PACB: Rentabilitas dodolan miturut bathi operasi|benitec.com - Margin operasi|DSGN - Margin operasi|RCKT: Margin operasi|FDMT (4D Molecular Therapeutics Inc) - Rentabilitas operasi|Margin dodolan operasi LXEO|Rentabilitas operasi KRRO|Margin operasi EDIT|SLN - Rentabilitas dodolan operasi|Margin operasi PRQR (ProQR)|CDXS - Margin dodolan operasi|Sangamo Therapeutics Inc. - Margin operasi|NAUT - Margin operasi|MGX: Margin operasi|Margin dodolan operasi Precision BioSciences, Inc.|GBIO (Generation Bio) - Margin operasi|Boundless Bio Inc. (BOLD) - Rentabilitas kegiatan operasi|Margin dodolan operasi XCUR (exicuretx.com)|Imunon Inc - Rentabilitas dodolan miturut bathi operasi|Margin operasi PHIO (Phio Pharmaceuticals Corp)|Tingkat bathi operasi MBIO|RNAZ - Rentabilitas operasi|Tingkat bathi operasi BNGO (bionanogenomics.com)|Applied DNA Sciences (APDN) - Rentabilitas operasi|Bluebird Bio - Tingkat bathi operasi|IPA (ImmunoPrecise Antibodies Ltd) - Margin operasi|Rentabilitas dodolan operasi Omega Therapeutics, Inc. OMGA|Margin operasi OMIC|RGLS (Regulus Therapeutics Inc.) - Tingkat bathi operasi|Telesis Bio - Margin dodolan operasi|Tingkat bathi operasi TCON|UBX - Rentabilitas operasi